Related Experiment Video
Updated: Feb 25, 2026
13:18
Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
Published on: March 3, 2023
1.8K
Development of a strategic model for integrating complementary medicines into professional pharmacy practice
Carolina Oi Lam Ung1, Joanna Harnett2, Hao Hu1
1State Key Lab of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao.
Research in Social & Administrative Pharmacy : RSAP
|August 9, 2017
Summary
Pharmacists identified key strategies for integrating traditional and complementary medicine (TM/CM) into pharmacy practice. Collaborative efforts in education, evidence, information resources, and workplace support are crucial for successful TM/CM integration.
Area of Science:
- Pharmacy Practice
- Integrative Medicine
- Healthcare Professional Development
Background:
- Traditional medicine (TM) and complementary medicine (CM) have grown significantly in pharmacy over two decades.
- Initiatives to integrate TM/CM into professional practice face persistent barriers.
- Quality use of all medicines, including TM/CM, remains a focus.
Purpose of the Study:
- To explore pharmacists' perspectives on resolving barriers to TM/CM integration in professional pharmacy practice.
- To identify actionable strategies for supporting professional services related to TM/CM products.
Main Methods:
- Qualitative study using three focus groups with 11 registered community pharmacists.
- Purposive and snowball sampling methods were employed for participant recruitment.
- Focus group discussions explored barriers and solutions for TM/CM integration.
Main Results:
- Pharmacists proposed five key stakeholders (organizations, universities, government, owners, pharmacists) drive integration.
- Four collaborative developments are essential: education/training, evidence building, reliable information resources, and workplace support.
- TM/CM manufacturers were not seen as collaborators by the pharmacists.
Conclusions:
- Findings support a strategic model for integrating TM/CM products into pharmacy practice.
- Collaboration among stakeholders is vital for overcoming barriers to TM/CM integration.
- Enhanced pharmacist support and resources are needed for quality TM/CM services.
More Related Videos
Related Concept Videos
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
39
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
39
01:20Pharmacokinetic Models: Overview
2.3K
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
2.3K
01:27Pharmacodynamic Models: Overview
35
Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
35
01:14Pharmacokinetic–Pharmacodynamic Relationship: Model Components
61
Pharmacokinetic-pharmacodynamic (PK–PD) modeling is essential in drug development and clinical pharmacology. It provides a quantitative framework to predict drug behavior and response over time. This approach integrates pharmacokinetics (PK), which describes the drug's absorption, distribution, metabolism, and excretion, with pharmacodynamics (PD), which characterizes the drug’s biological effects and mechanisms of action.The disposition kinetics of a drug determine its plasma...
61
01:06Three-Compartment Open Model
1.0K
The three-compartment open model is a pharmacokinetic model used to describe the distribution and elimination of drugs following extravascular administration. It comprises a central compartment representing the plasma and two peripheral compartments. The highly perfused peripheral compartment represents organs and tissues with a rich blood supply, such as the liver, kidneys, and lungs. The scarcely perfused peripheral compartment represents tissues with lower blood supply, such as adipose...
1.0K
01:29Pharmacodynamic Models: Direct Effect Model and Indirect Response Model
43
Pharmacodynamic models are essential tools in understanding the relationship between drug concentrations and their effects on biological systems. By characterizing the dynamics of drug action, these models guide dose selection, optimize therapeutic efficacy, and inform the development of new drugs. Two major classes of pharmacodynamic models include direct effect and indirect response models.Direct Effect ModelsDirect effect models describe the immediate relationship between drug concentration...
43